Mitochondrial disorders are a group of metabolic conditions caused by impairment of the oxidative phosphorylation system. There is currently no clear evidence supporting any pharmacological interventions for most mitochondrial disorders, except for coenzyme Q10 deficiencies, Leber hereditary optic neuropathy, and mitochondrial neurogastrointestinal encephalomyopathy. Furthermore, some drugs may potentially have detrimental effects on mitochondrial dysfunction. Drugs known to be toxic for mitochondrial functions should be avoided whenever possible. Mitochondrial patients needing one of these treatments should be carefully monitored, clinically and by laboratory exams, including creatine kinase and lactate. In the era of molecular and 'personalized' medicine, many different physicians (not only neurologists) should be aware of the basic principles of mitochondrial medicine and its therapeutic implications. Multicenter collaboration is essential for the advancement of therapy for mitochondrial disorders. Whenever possible, randomized clinical trials are necessary to establish efficacy and safety of drugs. In this review we discuss in an accessible way the therapeutic approaches and perspectives in mitochondrial disorders. We will also provide an overview of the drugs that should be used with caution in these patients.
Keywords: coenzyme Q10; drugs; mitochondria; mitochondrial diseases; mtDNA; toxicity.
Conflict of interest statement
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at http://www.drugsincontext.com/wp-content/uploads/2019/06/dic.212588-COI.pdf
Mitochondrial biogenesis: pharmacological approaches.Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118. Curr Pharm Des. 2014. PMID: 24606795
Drugs and mitochondrial diseases: 40 queries and answers.Expert Opin Pharmacother. 2012 Mar;13(4):527-43. doi: 10.1517/14656566.2012.657177. Epub 2012 Jan 31. Expert Opin Pharmacother. 2012. PMID: 22292617 Review.
Review of clinical trials for mitochondrial disorders: 1997-2012.Neurotherapeutics. 2013 Apr;10(2):307-19. doi: 10.1007/s13311-013-0176-7. Neurotherapeutics. 2013. PMID: 23361264 Free PMC article. Review.
Perspectives of drug-based neuroprotection targeting mitochondria.Rev Neurol (Paris). 2014 May;170(5):390-400. doi: 10.1016/j.neurol.2014.03.005. Epub 2014 May 1. Rev Neurol (Paris). 2014. PMID: 24792485 Review.
Increasing mtDNA levels as therapy for mitochondrial optic neuropathies.Drug Discov Today. 2018 Mar;23(3):493-498. doi: 10.1016/j.drudis.2018.01.031. Epub 2018 Jan 11. Drug Discov Today. 2018. PMID: 29337205